Nicox completed the Denali Phase 3 trial for NCX 470, targeting open-angle glaucoma and ocular hypertension. NCX 470 combines ...

Increased risk seen in adjusted analyses in association with nucleoside and nucleotide reverse transcriptase inhibitor use.

The daily use of eye drops containing 0.002% omidenepag isopropyl reduced intraocular pressure and was well‐tolerated in patients newly diagnosed with primary open‐angle glaucoma who had not ...

With more options available than ever to treat patients with glaucoma, it has become clearer that treatment needs to occur as early as possible to avoid the worst outcomes of the disease.Historically, ...

Press Release Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial Results expected mid-August to ...

Portugal: Researchers have found in a cross-sectional study from Portugal that pseudoexfoliation (PEX) syndrome is linked to ...

That’s why this Glaucoma Awareness Week (30th June - 6th July), Optical Express is urging Brits to take control of their eye ...

Press Release Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial Results expected mid-August to mid-September 2025 New Drug Application (NDA) submission in the ...

Qlaris Bio to showcase promising data on QLS-111, a novel glaucoma treatment, at the 2025 World Glaucoma Congress, ...

ViaLase, Inc., a medical technology company pioneering noninvasive femtosecond laser treatments for glaucoma, today announced key changes to its executive leadership team as the company prepares for ...